Saniona's partner Cadent Therapeutics presents pre-clinical data on CAD-1883 at the National Ataxia Foundations meeting in Philadelphia
See the poster here
See the poster here
Read more about the program here
Read more about Tesofensine here
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. Saniona has four programs in clinical development including three late stage clinical programs focused on the development of treatments to effectively regulate obsessions, cravings and addictions related to food and drugs. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome on its own and engage in partnerships with larger entities for development programs aiming to treat large indications such as obesity. The company’s research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona’s research center is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION).
Saniona share (OMX: SANION) is listed on Nasdaq Stockholm Small Cap
We have a broad portfolio of potential drug candidates in preclinical or clinical stages.
Tesofensine – monotherapy for the treatment of obesity...See more
Tesomet is in development for treatment of metabolic disorders...See more
NS2359 – a triple monoamine re-uptake inhibitor for treatment of cocaine abuse...See more
Potassium channels are important in for the function of the Purkinje cells of the cerebellum. Since Purkinje cells are the only output neurons from the cerebellar cortex they are essential for coordination of movement, balance and speech....See more
SAN711 for treatment of neuropathic pain and chronic itching...See more